Back

Long-term mortality benefit of CRT-D vs. CRT-P upgrade procedures from conventional devices without prior ventricular arrhythmias

23 April 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Optimization of CRT Cardiac Resynchronisation Therapy (CRT) EHRA Premium Access EHRA 2021

About the speaker

Photo
Doctor Walter Richard Schwertner

Semmelweis University Heart and Vascular Center, Budapest (Hungary)

5 More presentations in this session

Presentation thumbnail
Assessing survival and re-hospitalisation following transvenous lead extraction in cardiac resynchronisation therapy devices depending on reimplantation timing: a propensity score matched analysis.
Doctor V. Mehta (London, GB)
Abstract Slides Video
Presentation thumbnail
Impact of homeometric autoregulation using a stepwise change in heart rate on dP/dtmax and time to peak dP/dt with resynchronization therapy
Doctor H. Odland (Oslo, NO)
Abstract Video
Presentation thumbnail
Time delay to peak left ventricular pressure rise identifies the substrate for dyssynchronous heart failure and detects disease modification with resynchronization- an observational clinical study
Doctor H. Odland (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Electrocardiographic pattern in V1, aVL and I as predictor of events in heart failure following cardiac resincronization
Mr J. Asensio Nogueira (Burgos, ES)
Abstract Slides Video
Presentation thumbnail
Duration of the preejection phase is less preload dependent and therefore a better marker of acute response to cardiac resynchronization therapy than maximum pressure rise
Mr M. Villegas-Martinez (Oslo, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Optimization of CRT

The Event

Event poster

EHRA 2021

23 April - 25 April 2021
You may be interested in
thumbnail
Congress Presentation
Conduction system pacing in the current treatment of HFrEF patients
thumbnail
Congress Presentation
Device therapy: how to identify responders?
thumbnail
Congress Presentation
Cardiac resynchronisation therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources